Eli Lilly’s diabetes drug diminished weight and blood sugar in trial


Unlock this article by subscribing to STAT + and enjoy your first 30 days for free!


What is it?

STAT + is STAT’s premium subscription service for in-depth reporting and analysis across biotechnology, pharma, politics and life sciences. Our award-winning team covers the news on Wall Street, Washington policy developments, early scientific breakthroughs and clinical trial results, and health care disruptions in Silicon Valley and beyond.

What’s included

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerful team of reporters
  • Subscriber only newsletter
  • Daily newsletters that keep you informed of the day’s most important industry news
  • STAT + conversations
  • Weekly opportunity to have a live video chat with our reporters and leading industry experts
  • Exclusive industry events
  • Premium access to networking events only for subscribers across the country
  • The best reporters in the business
  • The most trusted and most connected healthcare newsroom
  • And much more
  • Exclusive interviews with industry leaders, profiles and premium tools like our CRISPR Trackr.